ESMO BC 2024

Medical Materials

Agenda

Coming soon

03:09 PM

Duration 70mins Berlin Hall

Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS pan BC: A Phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC)

Schmid P, Loi S, De la Cruz L, Yerushalmi R, Im SA, Sonnenblick A, Martinez M, Moreno I, Kennedy L, Griffiths K, Schwab R, Young F, Liao L, Dupree K, Kim SB

Oncology | Breast Cancer

Add to calendar

02:57 PM

Duration 70mins Berlin Hall

IMpassion132 double-blind randomised phase 3 trial of chemotherapy ± atezolizumab for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer

R. Dent, F. André, A. Gonçalves, M. Martin, P. Schmid, F. Schütz, S. Kummel, S.M. Swain, A. Bilici, D. Loirat, R. Villalobos Valencia, S.-A. Im, Y.H. Park, Z.K. Machackova, J. Mouta, R.J. Deurloo, X. Gan, M. Fan, A. Swat and J. Cortés

Oncology | Breast Cancer

Add to calendar

10:00 AM

Duration 60mins Berlin, Germany

Atezolimab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial

Huober J, Barrios CH, Niikura N, Jarzab M, Chang YC, SL Huggins-Puhalla, Pedrini J, Zhukova L, Curran M, Eiger D, Craine V, Lambertini C, Restuccia E, Zhang H

Oncology | Breast Cancer

Add to calendar

Duration 60mins Berlin, Germany

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre Phase III (neo)adjuvant FeDeriCa study

Jackisch C, Im S-A, Mattar A, Colomer R, Stroyakovskii D, Nowecki Z, De Laurentiis M, Pierga J-Y, Jung KH, Schem C, Heeson S, Crane V, Wang B, Restuccia E, Tan A

Oncology | Breast Cancer

Add to calendar

External site

ESMO BC 2024